A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

BackgroundHalf the children with high-risk neuroblastoma die with widespread metastases. Molecular radiotherapy is an attractive systemic treatment for this relatively radiosensitive tumor. 131I-mIBG is the most widely used form in current use, but is not universally effective. Clinical trials of 17...

Full description

Bibliographic Details
Main Authors: Fredrik Sundquist, Kleopatra Georgantzi, Kirsten Brunsvig Jarvis, Jesper Brok, Minna Koskenvuo, Jelena Rascon, Max van Noesel, Per Grybäck, Joachim Nilsson, Arthur Braat, Mikael Sundin, Sandra Wessman, Nikolas Herold, Lars Hjorth, Per Kogner, Dan Granberg, Mark Gaze, Jakob Stenman
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Pediatrics
Subjects:
neuroblastoma
relapse
refractory
177Lu-DOTATATE
PRRT
radiopharmaceutical
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.836230/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2022.836230/full

Similar Items